Roche's Avastin Pay-For Performance Deal: The Future Of German Health Care?
This article was originally published in The Pink Sheet Daily
Insurers have slammed a pay for performance proposal for Avastin in Germany, but it could be a cost-effective reimbursement model.
You may also be interested in...
Regional firm wins an important tender, but at a discount that is so steep it attacks the process as creating "only losers."
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.